Effects of astragalus injection on the TGFβ/Smad pathway in the kidney in type 2 diabetic mice

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Nie, Yanna ^a   Li, Shuyu ^a   Yi, Yuee ^a   Su, Weilian ^a   Chai, Xinlou ^a   Jia, Dexian ^a   Wang, Qian ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASTRAGALUS EXTRACT; CREATININE; GLUCOSE; MESSENGER RNA; SMAD PROTEIN; SMAD3 PROTEIN; SMAD7 PROTEIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; GLUCOSE BLOOD LEVEL; HERBACEOUS AGENT;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERGLYCEMIA; KIDNEY FUNCTION; KIDNEY PARENCHYMA; MALE; MORPHOMETRICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLYURIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ASTRAGALUS (PLANT); C57BL MOUSE; CHEMISTRY; COMPLICATION; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; KIDNEY; METABOLISM;

ANIMALS; ASTRAGALUS PLANT; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84900828237     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-148     Document Type: Article

References (38)

1. Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, Yoo SJ, Rouillon A, Weir MR. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the Microalbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48:17-26. 10.1007/s00125-004-1599-9, 15616801.
2. Wolf G, Ziyadeh FN. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron Physiol 2007, 106:26-31.
3. Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol 2011, 7:1056-1067.
4. Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-β2. Kidney Int 2000, 58:2367-2376. 10.1046/j.1523-1755.2000.00420.x, 11115070.
5. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB. Expression of transforming growth factor-βl in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989, 108:661-669. 10.1083/jcb.108.2.661, 2115426, 2645303.
6. Reeves WB, Andreoli TE. Transforming group factor-β contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 2000, 97:7667-7669. 10.1073/pnas.97.14.7667, 33997, 10884396.
7. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 1992, 41:107-114. 10.1038/ki.1992.14, 1593845.
8. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005, 10:48-56. 10.1111/j.1440-1797.2005.00334.x, 15705182.
9. Gagliardini E, Benigni A. Role of anti-TGF-β antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 2006, 17:89-96. 10.1016/j.cytogfr.2005.09.005, 16257566.
10. Ikushima H, Miyazono K. Cellular context-dependent " colors" of transforming growth factor-β signaling. Cancer Sci 2010, 101:306-312. 10.1111/j.1349-7006.2009.01441.x, 20067465.
11. Feng Y, Feng L. Protective effect of Astragalus membranaceus on diabetic nephropathy in rats. J Prac Med 2006, 22(21):2457-2459.
12. Xie W, Zhao Y, Zhang Y. Traditional Chinese medicines in treatment of patients with type 2 diabetes mellitus. Evid Based Complement Altern Med 2011, 726723. doi:10.1155/2011/726723.
13. Astragalus Natural medicines comprehensive database web site. Accessed at http://www.naturaldatabase.com on April 21, 2009, Astragalus.
14. Wang HY. Antifibrotic effect of the Chinese herbs Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci 2004, 74:1645-1658. 10.1016/j.lfs.2003.08.036, 14738908.
15. Li Y, Lai Y, Li S, Wu Y, Wang Q. Influence of huangqi injection on tubular epithelial-mesenchymal transition. J Beijing Univ Tradit Chin Med 2012, 35(2):109-116.
16. Li M, Wang W, Xue J, Gu Y, Lin S. Meta-analysis of the clinical value of astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol 2011, 133:412-419. 10.1016/j.jep.2010.10.012, 20951192.
17. Gui D, Huang J, Liu W, Guo Y, Xiao W, Wang N. Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways. Apoptosis 2013, 18:409-422. 10.1007/s10495-013-0801-2, 23325448.
18. Qi W, Niu J, Qin Q, Qiao Z, Gu Y. Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones 2014, 19:105-114. 10.1007/s12192-013-0438-7, 23719694.
19. Tervaert TW, Mooyaart AL. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 2010, 21:556-563. 10.1681/ASN.2010010010, 20167701.
20. Whiting DR, Guariguata L, Well C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321. 10.1016/j.diabres.2011.10.029, 22079683.
21. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003, 14:1358-1373. 10.1097/01.ASN.0000065640.77499.D7, 12707406.
22. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005, 16:S30-33. 10.1681/ASN.2004110970, 15938030.
23. Tomino Y. Lessons from the KK-Ay Mouse, a spontaneous animal model for the treatment of human type 2 diabetic nephropathy. Nephro-Urol Mon 2011, 4:524-525.
24. Zhang J, Xie X, Li C, Fu P. Systematic review of the renal protective effect of Astragalus (root) on diabetic nephropathy in animal models. J Ethnopharmacol 2009, 126:189-196. 10.1016/j.jep.2009.08.046, 19735713.
25. Liao WP, Shi YG. Effect of astragalus polysaccharides and soy isoflavones on glucose metabolism in diabetic rats. Acta Acad Med Militaris Tertiae 2007, 29:416-418.
26. Zhou F, Mao XQ, Wang N, Liu J, Ou-Yang JP. Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK. Acta Pharmacol Sin 2009, 30:1607-1615. 10.1038/aps.2009.168, 19960007.
27. Petersen J, Ross J, Rabkin R. Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 1988, 37:1346-1350. 10.2337/diab.37.10.1346, 2970981.
28. Xiao M, Li H, Xie X. Astragalus Mongholicus may regulate rat renal tubular cell transdifferrentiation induced by TGF-β1 through C- met dependent pathway. Chin J Integr Tradit West Nephrol 2008, 9:764-768.
29. Li S, Chai X, Wu Y, Jia D, Hao Y, Su W, Wang Q. Effects of astragalus injection combined with puerarin injection on expression of BMP-7 and TGF-β1 in type 2 diabetic KKAy mouse kidney. Chin J Pathophysiol 2012, 28:1802-1806.
30. Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med 2010, 235:383-391.
31. Hong SW, Isono M, Chen S, Ziyadeh FN. Increased glomerular and tubular expression of TGF-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001, 158:1653-1663. 10.1016/S0002-9440(10)64121-1, 1891936, 11337363.
32. Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts IS, Mundel P, Bottinger EP. Inhibitory smads and TGF-beta signaling in glomerular cells. J Am Soc Nephrol 2002, 13:2657-2666. 10.1097/01.ASN.0000033276.06451.50, 12397035.
33. Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 2009, 24:1443-1454. 10.1093/ndt/gfn699, 19096081.
34. Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, Lan HY. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 2011, 60:590-601. 10.2337/db10-0403, 3028360, 20980457.
35. Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, Laping NJ, Chen S. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 2007, 293:F1657-1665. 10.1152/ajprenal.00274.2007, 17804483.
36. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 2003, 305:1002-1007. 10.1016/S0006-291X(03)00885-4, 12767930.
37. Arany PR, Flanders KC, DeGraff W, Cook J, Mitchell JB, Roberts AB. Absence of Smad3 confers radioprotection through modulation of ERK-MAPK in primary dermal fibroblasts. J Dermatol Sci 2007, 48:35-42. 10.1016/j.jdermsci.2007.05.012, 2016790, 17624738.
38. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, Yamashiro Y, Ogawa H, Nakao A. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004, 66:597-604. 10.1111/j.1523-1755.2004.00779.x, 15253712.